Contrast injector technology firm Medrad has signed an FDG research agreement with the University of South Florida (USF).
Clinicians at Moffitt Cancer Center in Tampa will use the Warrendale, PA-based vendor's Intego PET infusion system to measure and infuse patient-specific FDG doses, while industrial engineers from USF will gather and analyze workflow data, according to Medrad.
The study is designed to compare manual infusion to automated infusion, and to quantify time, cost, and labor savings from process improvements provided by automated FDG infusion, Medrad said.
Related Reading
Medrad debuts contrast reporting software, June 4, 2009
Medrad boosts service offerings, March 20, 2009
Confirma, Medrad ink deal, March 6, 2009
Medrad expands multivendor service offering, February 9, 2009
Medrad sponsors Swiss PET project, January 6, 2009
Copyright © 2009 AuntMinnie.com